MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 69 filers reported holding MEREO BIOPHARMA GROUP PLC in Q1 2021. The put-call ratio across all filers is 1.19 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $168,474 | -2.2% | 130,600 | +0.1% | 0.00% | 0.0% |
| Q2 2023 | $172,260 | +51.7% | 130,500 | -18.7% | 0.00% | 0.0% |
| Q1 2023 | $113,527 | -3.0% | 160,600 | +2.9% | 0.00% | 0.0% |
| Q4 2022 | $117,000 | -10.0% | 156,000 | +3.0% | 0.00% | 0.0% |
| Q3 2022 | $130,000 | -83.8% | 151,400 | -78.8% | 0.00% | -87.5% |
| Q2 2022 | $802,000 | -18.5% | 715,696 | -18.6% | 0.01% | -11.1% |
| Q1 2022 | $984,000 | -14.7% | 879,123 | +22.0% | 0.01% | -10.0% |
| Q4 2021 | $1,154,000 | -41.9% | 720,793 | -12.2% | 0.01% | -52.4% |
| Q3 2021 | $1,986,000 | -52.7% | 820,793 | -38.1% | 0.02% | -53.3% |
| Q2 2021 | $4,200,000 | -2.1% | 1,325,053 | +4.1% | 0.04% | -13.5% |
| Q1 2021 | $4,291,000 | +3.5% | 1,273,053 | +9.9% | 0.05% | -7.1% |
| Q4 2020 | $4,145,000 | +361.1% | 1,158,000 | +237.4% | 0.06% | +229.4% |
| Q3 2020 | $899,000 | – | 343,195 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 1,854,278 | $6,638,000 | 3.61% |
| Asymmetry Capital Management, L.P. | 739,812 | $2,649,000 | 1.21% |
| Affinity Asset Advisors, LLC | 625,000 | $2,238,000 | 1.19% |
| Tri Locum Partners LP | 728,710 | $2,609,000 | 0.95% |
| Boxer Capital, LLC | 6,226,673 | $22,291,000 | 0.72% |
| DAFNA Capital Management LLC | 668,148 | $2,392,000 | 0.71% |
| Vivo Capital, LLC | 4,220,938 | $15,111,000 | 0.67% |
| Delphi Management Partners VIII, L.L.C. | 256,734 | $919,000 | 0.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 280,000 | $1,002,000 | 0.58% |
| Rubric Capital Management LP | 1,853,417 | $6,635,000 | 0.49% |